H. Lundbeck A/S

H. Lundbeck A/S

HLBBF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$8.68B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
H. Lundbeck A/SH. Lundbeck A/S14.51.94%14%0.30.3

Earnings Call Q3 2026

November 11, 2026 - AI Summary

Strong Q3 / 9M performance; guidance raised (core investor takeaway) - 9 months revenue: DKK 20.2bn, +13% at constant exchange rates (underlying growth +11%). - Adjusted EBITDA: +19% (driven mainly by Vyepti performance and favorable gross profit dynamics; some offset from higher R&D). - Full-year outlook raised: Revenue growth 11–12% and adjusted EBITDA growth 15–19% (both at constant exchange rates). - Main reason for confidence: stronger-than-expected Vyepti demand and partner markets tracking better than expected; additional visibility from Q3. - Modeling updates (watch items): reported adjusted EBITDA growth now expected ~9 percentage points below constant FX vs previously ~8; adjusted gross margin 86–87%, R&D DKK 5.6–5.7bn, D&A ~DKK 1.9bn, tax 21–24%.
Vyepti (anti-CGRP migraine) delivering major growth momentum + geographic expansion opportunity - 9 months Vyepti revenue: DKK 4.533bn, +45% at constant exchange rates. - U.S. growth: +46%; demand growth 39.3% vs market 15.6%—outperformance driven by new patient starts, strong conversion, and best-in-class persistency. - Europe/international: +41% at constant FX; gaining >2 percentage points share YoY (notably France ~7% share and Spain ~13%). - Surprising/positive catalyst: Japan marketing approval received, with launch planned by end of 2026 (new chapter + Asia opportunity). Management said first 6–8 months will be key to judge trajectory; hasn’t quantified peak yet. - Strategic “where growth comes from” (not a number but important): highest uptake opportunity is moving up the treatment paradigm (from later lines into 2nd/3rd line), which management says is ~4.2x value per market-share point vs later lines (implies meaningful upside if penetration continues).
Rexulti (TRx) resilient growth despite competition; aging/65+ segment expanding - 9 months Rexulti revenue: DKK 5.1bn, +13% at constant exchange rates. - U.S. TRx demand: +15.1% YTD through Aug 2026. - Growth drivers: AAD remains key (TRx +29% YTD) and MDD also contributes (+13.7%). - 65+ segment: 37% of total Rexulti TRx and expanding → supports longer-term growth potential. - Europe/international: +18% at constant FX, continued momentum in key markets. - Risk context (implied): management noted an increasingly competitive market, but execution appears holding the plan.

Exclusive for Stockcircle Pro members

Sign upSign Up
$26.57

Current Fair Value

203.7% upside

Undervalued by 203.7% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$8.68 Billion
Enterprise Value$13.67 Billion
Annual dividend$0.18
Dividend yield1.94%
Earnings per Share$3.21
Beta0.26
Outstanding Shares992,149,181

Return

Return on Equity14.32%ROE
Return on Assets7.51%
Return on Invested Capital15.17%

Valuation & Multiples

P/E Ratio14.54P/E Ratio
PEG96.41PEG
Price to Sales0.34Price to Sales
Price to Book Ratio0.31Price to Book Ratio
Enterprise Value to Revenue0.52
Enterprise Value to EBIT2.05
Enterprise Value to Net Income3
Total Debt to Enterprise0.63
Debt to Equity0.31Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 11, 2026
EPS Estimate
$0.17
Consensus analyst estimate
Revenue Estimate
$957.44 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 10, 2027
EPS Estimate
$0.12
Consensus analyst estimate
Revenue Estimate
$914.85 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About H. Lundbeck A/S

5,214 employees
CEO: Charl van Zyl

H. Lundbeck A/S operates as an international biopharmaceutical entity, focusing its efforts on the entire lifecycle of pharmaceutical products—from initial research and development to manufacturing and global sales. The firm primarily sp...